ResearcherUniversity Hospital Schleswig-HolsteinActive in the last 2 years
David P. Witte
Matched on ORCID iD 0009-0004-7771-4148; OpenAlex author ID A5109916335. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 25
2016: 2 papers · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper
Papers 4
- Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO … Co-author DOI 10.1007/s00432-024-05954-5↗
- 68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial. Co-author DOI 10.2967/jnumed.122.264827↗
- Proteinase-activated receptor 2 promotes TGF-β-dependent cell motility in pancreatic cancer cells by sustaining expression of the TGF-β type I receptor ALK5. First author DOI 10.18632/oncotarget.9600↗
- Proteinase-Activated Receptor 2 Is a Novel Regulator of TGF-β Signaling in Pancreatic Cancer. Co-author DOI 10.3390/jcm5120111↗
Closest collaborators
The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Céline Lugnier · 2 shared papers, 2023–2024 · strength 0.30
- Paper Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a … DOI 10.1007/s00432-024-05954-5↗
- Paper 68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-… DOI 10.2967/jnumed.122.264827↗
- Anke Reinacher‐Schick · 2 shared papers, 2023–2024 · strength 0.30
- Paper Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a … DOI 10.1007/s00432-024-05954-5↗
- Paper 68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-… DOI 10.2967/jnumed.122.264827↗
- Janna-Lisa Velthaus · 1 shared paper, 2024 · strength 0.15
- Sabrina Sulzer · 1 shared paper, 2024 · strength 0.15
- Stefanie Hegenberg · 1 shared paper, 2024 · strength 0.15
- Annika Kurreck · 1 shared paper, 2024 · strength 0.15
- Heiko Becker · 1 shared paper, 2024 · strength 0.15
- Maximilian Reichert · 1 shared paper, 2024 · strength 0.15
- Timm M. Reißig · 1 shared paper, 2024 · strength 0.15
- Sebastian Lange · 1 shared paper, 2024 · strength 0.15
- Arndt Vogel · 1 shared paper, 2024 · strength 0.15
- Klara Dorman · 1 shared paper, 2024 · strength 0.15
- Georg Beyer · 1 shared paper, 2024 · strength 0.15
- Christoph Benedikt Westphalen · 1 shared paper, 2024 · strength 0.15
- Wolfgang P. Fendler · 1 shared paper, 2023 · strength 0.15
- Waldemar H. Uhl · 1 shared paper, 2023 · strength 0.15
- Kim Magaly Pabst · 1 shared paper, 2023 · strength 0.15
- Ken Herrmann · 1 shared paper, 2023 · strength 0.15
- Lukas Kessler · 1 shared paper, 2023 · strength 0.15
- Jens Thomas Siveke · 1 shared paper, 2023 · strength 0.15
- Franziska Zeeh · 2 shared papers, 2016 · strength 0.11
- Hendrik Lehnert · 2 shared papers, 2016 · strength 0.11
- Hendrik Ungefroren · 2 shared papers, 2016 · strength 0.11
- Utz Settmacher · 2 shared papers, 2016 · strength 0.11
- Evelin Grage‐Griebenow · 1 shared paper, 2016 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.